Business News • PR NewsWire • Study at ASCO Shows Novartis Drug Afinitor® First to Shrink SEGA Brain Tumors in Children and Adults With Tuberous Sclerosis

Study at ASCO Shows Novartis Drug Afinitor® First to Shrink SEGA Brain Tumors in Children and Adults With Tuberous Sclerosis

Study at ASCO Shows Novartis Drug Afinitor® First to Shrink SEGA Brain Tumors in Children and Adults With Tuberous Sclerosis

EAST HANOVER, N.J., June 5 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") announced today that results from a Phase II study show Afinitor® (everolimus) tablets is the first medication in a clinical trial to decrease the size of subependymal giant cell astrocytomas (SEGAs), b

View More : http://www.prnewswire.com/news-releases/study-at-asco-shows-novartis-drug-afinitor-first-to-shrink-sega-brain-tumors-in-...

Releted News by prnewswire

Delcath Highlights Phase III Trial Results Presented at ASCO

Pharmacyclics Announces Presentation of Results From Phase I Trial of Its First-in-Human Btk Inhibitor: PCI-32765

U.S. Census Bureau Daily Feature for June 6

Queen Meg, Registered Nurses, and Everyday Californians Greet Meg Whitman, Pete Wilson in Fresno, Sacramento areas Sunday